Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer

摘要

The present invention is a pharmaceutical combination that may be useful for the treatment of diseases involving cell proliferation, in particular metastatic colorectal cancer, comprising 3-Z- [1- (4- (N-((4-methyl-piperazine- 1-yl) -methylcarbonyl) -N-methyl-amino) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, 2'-deoxy- 5- (trifluoromethyl) uridine or a pharmaceutically acceptable salt thereof, and 5-chloro-6-[(2-iminopyrrolidin-1-yl) methyl] pyrimidine-2,4 (1H, 3H) -dione Or 2'-deoxy-5- (trifluoromethyl) uridine or a pharmaceutically acceptable salt thereof, 5-chloro-6-[(2-iminopyrrolidine-), or a pharmaceutically acceptable salt thereof; 1- ) Methyl] pyrimidine-2,4 (IH, 3H) - the molar ratio of dione or a pharmaceutically acceptable salt thereof is 1: 0.5, a pharmaceutical combination.